Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDEA.L Regulatory News (IDEA)

  • There is currently no data for IDEA

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

COVID-19 Trading Update

7 Apr 2020 07:00

RNS Number : 9803I
Ideagen PLC
07 April 2020
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

April 7th 2020

Ideagen PLC

("Ideagen" the "Company" or the "Group")

COVID-19 Trading Update 

Ideagen PLC (AIM: IDEA), a leading supplier of Integrated Risk Management software to highly regulated industries, provides an update on trading and progress in the year to 30 April 2020 against the backdrop of a rapidly changing economic and public health environment.

Financial year to 30 April 2020

The Group continued its strong first half trading momentum through the third quarter to the end of January 2020. Since then, the Group has won new customers within the Internal Audit, UK Healthcare, Life Sciences and US Federal markets. Conversely, investment decisions and timing of deployments within aviation and manufacturing, particularly automotive and aerospace supply chains, have been significantly impacted by the increasing government restrictions and market dynamics.

Ideagen's software is considered 'business critical' by its customers and as such recurring "Software as a Service" and Support and Maintenance revenues have not been affected. Non-recurring revenue, consisting of perpetual licence and implementation services, has seen some impact. In this light, the Company expects to report revenues for the year of approximately £56m (only slightly below previous expectations of £58.5m). The impact has been partially offset by lower operating expenditure and therefore adjusted EBITDA is expected to be broadly in line with consensus expectations at approximately £18.5m on an IFRS16 basis (this represents an increase of 29% on the last financial year) or approximately £17.5m on a like-for-like IAS17 basis (being a 22% increase on the last financial year). In addition, the Board is considering making a general provision of approximately £2m against receivables given uncertainties in the industries in which some of the Group's clients operate. The need for a provision and its quantum will be determined by the Company's experience over the coming months.

The Group's balance sheet and funding position is strong and the Board has a significant degree of comfort for the next financial year. Cash collection in the second half has remained robust (including March, a month of significant wider disruption) and in line with management expectations. Should this trend continue through to year end, the Board expects gross cash to be approximately £7m and gross bank borrowings (excluding IFRS16 leases) of approximately £25m at that date, with undrawn facilities of approximately a further £15m. Net bank debt at that date would therefore be in line with expectations and be comfortably within the relevant banking covenant.

The Board intends to continue to pay a dividend in line with the Group's progressive dividend policy. The interim dividend for the current financial year was paid as planned in March 2020.

Outlook for year to 30 April 2021

Given the unprecedented economic and social disruption that COVID-19 has created, particularly with respect to March and April (historically the Group's most productive sales months), the Board is pleased with the Company's resilient performance and robust position entering the new financial year. This is testament to the strength of the Group's business model, the defensive markets in which we operate and, of course, the character and determination of our employees.

The Board has taken pragmatic measures to ensure that its cost base is aligned with a cautious outlook in an uncertain economic and social environment. Measures including limited redundancies, salary freezes and operational efficiencies, have been taken to reduce the forecast annual cost base by approximately £4m which, on the basis of an expected run-rate of revenues of £15m per quarter will enable the Group to meet market expectations for adjusted EBITDA for the year to 30 April 2021. The quarterly run-rate revenue assumption of £15m is based on the expected out-turn for the final quarter of the current financial year and includes £12m of recurring revenues. The Group expects to have a run-rate book of annual recurring revenues at 30 April 2020 of approximately £49m.

 

Employees and stakeholders

The Ideagen team has pulled together in this challenging environment and the health and safety of our employees is our primary concern. All colleagues have moved to a home working environment and all offices across the globe are now closed until further notice. The business continues to operate effectively due to our tight integration and investment in cloud-based IT infrastructure and our business continuity and risk management plan is available to all customers on our customer portal. The Board are tremendously grateful for the efforts of its employees and stakeholders.

Ben Dorks, CEO, commented: ''Whilst our performance in our fourth quarter has been affected by the current crisis our strategy and business model remain robust and I am proud of our execution at this difficult time. We have acted quickly and decisively to realign our 2020/2021 cost model to current trading patterns which we believe will provide the basis for a robust financial performance in our next financial year.

We believe that the Group is now well placed to manage its business risk effectively, emerge from the current environment in good health able to take advantage of business opportunities once the pandemic has subsided. I would like to thank all of our employees, customers and investors for their support during this time as we look forward to the economic and public health environment normalising in the future.''

 

Enquiries:

 

Ideagen plc

01629 699100

David Hornsby, Executive Chairman

Ben Dorks, Chief Executive

 

Graeme Spenceley, Chief Financial Officer

 

 

 

finnCap Limited

020 7220 0500

Henrik Persson, James Thompson (Corporate Finance)

 

Alice Lane (ECM)

 

 

 

Canaccord Genuity Limited

020 7523 8000

Simon Bridges

 

Richard Andrews

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDBQLLBBZLFBBL
Date   Source Headline
22nd Oct 201911:26 amRNSHolding(s) in Company
17th Oct 20193:32 pmRNSDirector/PDMR Shareholding
11th Oct 20197:00 amRNSAcquisition of Optima Diagnostics Limited
7th Oct 20193:29 pmRNSNotice of AGM
4th Oct 201910:45 amRNSExercise of Options, Issue of Shares and TVR
1st Oct 20197:00 amRNSExercise of Options, Issue of Shares and TVR
25th Sep 20197:00 amRNSRedland Acquisition Update - New Contract Wins
17th Sep 20197:00 amRNSDirector Dealing and Total Voting Rights
13th Sep 201912:08 pmRNSIssue of shares under the Share Incentive Plan
3rd Sep 20198:48 amRNSHolding(s) in Company
27th Aug 20192:21 pmRNSExercise of Options and Issue of Shares
14th Aug 20194:04 pmRNSIssue of New Shares under the Share Incentive Plan
30th Jul 201912:26 pmRNSHolding(s) in Company
22nd Jul 20194:20 pmRNSIssue of New Shares under the Share Incentive Plan
17th Jul 20197:00 amRNSPreliminary Results
19th Jun 201910:24 amRNSHolding(s) in Company
10th Jun 20197:00 amRNSAcquisition of Redland Solutions Ltd
30th May 20197:00 amRNSContract Award with New Tier 1 Airline Customer
15th May 20197:00 amRNSCapital Markets Day
14th May 20197:00 amRNSTrading Statement
12th Apr 20192:43 pmRNSDirector Dealings
11th Apr 20195:06 pmRNSIssue of Shares, Director Dealings and TVR
29th Mar 20197:00 amRNSExtension to 2018 Long Term Incentive Plan awards
25th Feb 20198:00 amRNSExercise of Options and Issue of Shares
30th Jan 201910:03 amRNSExercise of Options and issue of shares
28th Jan 20194:33 pmRNSIssue of new shares under the Share Incentive Plan
22nd Jan 20197:00 amRNSUnaudited Interim Results
21st Jan 20198:46 amRNSHolding(s) in Company
15th Jan 20197:00 amRNSAppointment of Joint Broker
14th Jan 20197:00 amRNSAcquisition of Scannell Solutions Ltd
11th Dec 20183:37 pmRNSIssue of Shares, Director Dealings and TVR
5th Dec 20182:54 pmRNSHolding(s) in Company
22nd Nov 201812:12 pmRNSHolding(s) in Company
21st Nov 20187:57 amRNSHolding(s) in Company
20th Nov 201812:04 pmRNSHolding(s) in Company
19th Nov 20185:56 pmRNSHolding(s) in Company
13th Nov 20187:00 amRNSTrading Update
30th Oct 20182:28 pmRNSResult of AGM
24th Oct 20182:35 pmRNSExercise of Options and Total Voting Rights
23rd Oct 201811:19 amRNSHolding(s) in Company
23rd Oct 20187:00 amRNS2018 Long Term Incentive Plan awards
12th Oct 20183:26 pmRNSHolding(s) in Company
10th Oct 20184:18 pmRNSHolding(s) in Company
8th Oct 201812:46 pmRNSIssue of Shares and Total Voting Rights
8th Oct 20187:00 amRNSPosting of Annual Report and Notice of AGM
5th Oct 20187:00 amRNSDirectors' Dealings
3rd Oct 20184:36 pmRNSExercise of Options & Total Voting Rights
2nd Oct 20184:38 pmRNSHolding(s) in Company
2nd Oct 20184:37 pmRNSHolding(s) in Company
28th Sep 20187:00 amRNSAcquisition of Morgan Kai Group Ltd

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.